All In Biotech

Drug Trial Radar · NCT05083923

A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)

An Open-Label, Single-Arm, Multicenter, Phase 3 Study to Evaluate the Safety and Tolerability, and Pharmacokinetics of Diroximel Fumarate (BIIB098) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Oct 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

136

Actual

Start

Nov 18, 2021

Primary completion

Sep 11, 2024

Study completion Sep 11, 2024

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Oct 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of this study are to determine the safety and tolerability of DRF administered for up to 24 weeks in adult East Asian participants with RMS (Part 1) and to determine the safety and tolerability of DRF administered for up to 48 weeks in adult East Asian participants with RMS (Part 2). The secondary objective of this study is to evaluate the pharmacokinetic(s) (PK) of DRF metabolites (monomethyl fumarate \[MMF\] and 2-hydroxyethyl succinimide \[HES\]) following multiple doses of DRF in a subset of adult East Asian participants with RMS (Part 1).

Conditions

  • Relapsing Forms of Multiple Sclerosis

Interventions

  • Diroximel fumarateDrug

    Administered as specified in the treatment arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)Time frame: Baseline (Day 1) up to Week 24 (for prematurely discontinued participants, AEs were reported up to 2 weeks post discontinuation)
  2. Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Laboratory ParametersTime frame: Baseline (Day 1) to Week 24
  3. Part 1: Number of Participants With Abnormal Shift in 12-Lead Electrocardiogram (ECG) ValuesTime frame: Baseline (Day 1) to Week 24
  4. Part 1: Number of Participants With Clinically Relevant Abnormalities in Vital Sign ParametersTime frame: Baseline (Day 1) to Week 24
  5. Part 1: Number of Participants With Columbia Suicide Severity Rating Scale (C-SSRS) EventsTime frame: Baseline (Day 1) to Week 24
  6. Parts 1 and 2: Number of Participants With TEAEs and TESAEsTime frame: From Day 1 up to the end of the study (up to Week 50)
  7. Part 2: Number of Participants With Potentially Clinically Significant Abnormalities in Laboratory ParametersTime frame: Baseline (Day 1) to Week 48
  8. Part 2: Number of Participants With Abnormal Shift in 12-Lead ECG ValuesTime frame: Baseline (Day 1) to Week 48
  9. Part 2: Number of Participants With Clinically Relevant Abnormalities in Vital Sign ParametersTime frame: Baseline (Day 1) to Week 48
  10. Part 2: Number of Participants With C-SSRS EventsTime frame: Baseline (Day 1) to Week 48

Locations

52 sites in 2 countries. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Beijing Hospital

    Beijing, Beijing Municipality, China

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

  • Lanzhou University Second Hospital

    Lanzhou, Gansu, China

  • Dongguan People's Hospital

    Dongguan, Guangdong, China

  • The First Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Guangzhou First People's Hospital

    Guangzhou, Guangdong, China

  • The Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • The Third Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Tangshan Gongren Hospital

    Tangshan, Hebei, China

  • The First Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • The Second Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Xiangya Hospital, Central South University

    Changsha, Hu'nan, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

    Wuhan, Hubei, China

  • The Affiliated Hospital of Inner Mongolia Medical University

    Hohhot, Inner Mongolia, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • Jiangxi Provincial People's Hospital

    Nanchang, Jiangxi, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • Shengjing Hospital of China Medical University

    Shengyang, Liaoning, China

  • General Hospital of Ningxia Medical University

    Yinchuan, Ningxia Hui, China

  • Tangdu Hospital, Fourth Military Medical University

    Xi'an, Shan'xi, China

  • Renji Hospital Shanghai Jiaotong University School of Medicine - West Branch

    Shanghai, Shanghai Municipality, China

  • Shanxi Provincial People's Hospital

    Taiyuan, Shanxi, China

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

  • Tianjin Medical University Affiliated General Hospital

    Tianjin, Tianjin Municipality, China

  • First Affiliated Hospital of Kunming Medical University

    Kunming, Yun'nan, China

  • Chiba University Hospital

    Chiba, Chiba, Japan

  • Tokyo Womens Medical University Yachiyo Medical Center

    Yachiyo, Chiba, Japan

  • Ehime University Hospital

    Toon-shi, Ehime, Japan

  • Fukuoka University Hospital

    Fukuoka, Fukuoka, Japan

  • Hospital of the University of Occupational and Environmental Health

    Kitakyushu-shi, Fukuoka, Japan

  • Southern Tohoku Medical Clinic

    Koriyama-shi, Fukushima, Japan

  • NHO Asahikawa Medical Center

    Asahikawa-shi, Hokkaido, Japan

  • Obihiro Kosei Hospital

    Obihiro, Hokkaido, Japan

  • NHO Hokkaido Medical Center

    Sapporo, Hokkaido, Japan

  • University of Tsukuba Hospital

    Tsukuba, Ibaraki, Japan

  • Iwate Medical University Uchimaru Medical Center

    Morioka, Iwate, Japan

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.